Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy

Blood Adv. 2022 Jan 25;6(2):686-689. doi: 10.1182/bloodadvances.2021006112.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD19
  • COVID-19 Vaccines*
  • COVID-19*
  • Humans
  • Immunity
  • Immunotherapy, Adoptive
  • Neoplasm Recurrence, Local
  • SARS-CoV-2
  • Vaccination

Substances

  • Antigens, CD19
  • COVID-19 Vaccines